---
layout: default
title: Ascorbic Acid
parent: 僅模型預測 (L5)
nav_order: 56
evidence_level: L5
indication_count: 10
---

# Ascorbic Acid
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ascorbic Acid: From Vitamin C Deficiency to Non-Syndromic Esophageal Malformation

## One-Sentence Summary

Ascorbic Acid is the active form of Vitamin C, an essential nutrient whose primary classical indication is the prevention and treatment of vitamin C deficiency (scurvy) and nutritional supplementation.
The TxGNN model ranks **Non-Syndromic Esophageal Malformation** as its top novel repurposing prediction with a model score of **99.96%**,
yet **no clinical trials and no supporting publications** exist for this specific direction — placing this prediction at the lowest possible evidence tier (L5).

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Vitamin C deficiency (scurvy) and nutritional supplementation |
| Predicted New Indication | Non-Syndromic Esophageal Malformation |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, Ascorbic Acid (Vitamin C) is an obligatory co-factor for prolyl-4-hydroxylase and lysyl hydroxylase — enzymes that catalyze the post-translational modifications essential for collagen triple-helix stability and cross-linking. It also acts as a potent water-soluble antioxidant, an enhancer of non-heme iron absorption, and crucially, a co-factor for TET family dioxygenases that mediate epigenetic DNA demethylation. This last role has growing relevance to developmental biology, as TET-mediated epigenetic reprogramming is critical during early embryogenesis.

Non-syndromic esophageal malformation encompasses congenital structural anomalies of the esophagus — including esophageal atresia and tracheo-esophageal fistula — occurring without associated syndromic features. The theoretical basis for the TxGNN prediction rests on two possible mechanistic threads: first, that Vitamin C's co-factor role in collagen maturation could influence esophageal connective tissue formation during embryonic development; second, that TET-mediated epigenetic programming could modulate foregut progenitor cell differentiation. Supporting the developmental importance of Vitamin C more broadly, knockout studies of the ascorbic acid brain transporter (Slc23a1) in mice confirm that Vitamin C availability is essential for perinatal survival.

However, the link to esophageal malformation specifically is entirely speculative. These structural congenital defects arise from embryological patterning failures governed by genetic programs — principally Shh, Wnt, and Notch signaling cascades — rather than nutritional substrate availability. No esophageal malformation phenotype has been reported in any Vitamin C-deficient animal model, and no human epidemiological data associate maternal Vitamin C status with this condition. The high TxGNN score most likely reflects broad network connectivity between Vitamin C metabolism nodes and esophageal disease nodes in the underlying knowledge graph, rather than a specific pharmacological relationship. This prediction should be treated as a hypothesis-generating signal only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for ascorbic acid in non-syndromic esophageal malformation.

---

## Literature Evidence

Currently no related literature available for this indication.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Non-syndromic esophageal malformation is a structural congenital defect with genetic and embryological origins that are mechanistically disconnected from the pharmacological actions of Vitamin C supplementation. With zero supporting preclinical or clinical evidence, this repurposing direction cannot progress without fundamental hypothesis validation from the ground up.

**To proceed, the following is needed:**
- Animal model studies examining whether maternal Vitamin C deficiency or high-dose supplementation during early gestation affects the incidence or severity of esophageal malformations
- Epidemiological data assessing whether maternal Vitamin C status correlates with non-syndromic esophageal malformation incidence in human cohorts
- Mechanistic studies clarifying whether esophageal foregut morphogenesis is sensitive to ascorbic acid availability — particularly via collagen maturation or TET-mediated epigenetic pathways
- Complete drug mechanism of action (MOA) data from DrugBank (currently absent from this dataset)
- Safety profile, key warnings, and contraindications retrieved from the product package insert
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

